{"product_id":"collegiumpharma-marketing-mix","title":"Collegium Pharmaceutical Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuilt for Strategy. Ready in Minutes.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical’s product innovation, pricing strategy, targeted distribution, and clinical-focused promotion create a differentiated position in specialty pain management; the full 4Ps Marketing Mix Analysis unpacks these elements with data-driven insights and tactical recommendations—download the editable, presentation-ready report to save hours and apply proven strategies to your work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDifferentiated Pain Management Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical’s differentiated pain management portfolio centers on Xtampza ER, an abuse-deterrent extended‑release opioid using proprietary DETERX technology that resists crushing and dissolving to curb misuse.\u003c\/p\u003e\n\u003cp\u003eBy end‑2025 Collegium solidified leadership in chronic pain alternatives, reporting net product sales of $245 million in 2024 and projected mid‑2025 market share gains versus traditional opioids.\u003c\/p\u003e\n\u003cp\u003eThe portfolio targets a major public health need by providing effective analgesia while lowering risks of respiratory depression and overdose from tampering, supported by clinical and pharmacovigilance data showing reduced tamperability metrics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Expansion into CNS and ADHD\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing the 2021 acquisition of Ironshore Therapeutics, Collegium added Jornay PM to its portfolio, entering the ADHD market and reducing pain-segment reliance; ADHD sales contributed to a 2024 product mix shift with estimated ADHD revenue of ~$40M driving total 2024 net product revenue to $266M.\u003c\/p\u003e\n\u003cp\u003eJornay PM’s evening dosing delivers symptom control at waking, serving pediatric and adult niches and differentiating from morning stimulants; clinical adoption reached ~22% of targeted ADHD prescribers by end-2024, aided by Collegium’s specialty sales force.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNucynta Franchise Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Nucynta franchise, comprising Nucynta ER (extended-release) and Nucynta IR (immediate-release), drove ~45% of Collegium Pharmaceutical’s product revenue in 2024, remaining a core revenue source through 2025.\u003c\/p\u003e\n\u003cp\u003eBoth formulations use a dual mechanism—mu-opioid receptor agonism plus N-methyl-D-aspartate (NMDA) antagonism—proven effective for neuropathic and chronic pain in multiple phase III and real-world studies.\u003c\/p\u003e\n\u003cp\u003eCollegium invested roughly $20–25M annually in life-cycle management and REMS (risk evaluation and mitigation strategy) updates in 2023–2025 to delay generic erosion and defend market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBelbuca and Buprenorphine Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBelbuca (buprenorphine buccal film) is a core growth pillar for Collegium, offering a Schedule III opioid with lower addiction and withdrawal risk versus Schedule II agents; 2024 US net sales for Belbuca were about $72m, up ~8% from 2023.\u003c\/p\u003e\n\u003cp\u003eThe buccal film delivers high bioavailability and better adherence for around-the-clock analgesia; buprenorphine’s ceiling effect reduces respiratory depression risk, supporting safer chronic pain use.\u003c\/p\u003e\n\u003cp\u003eRegulatory trends since 2022 favor less-restrictive opioid options for long-term therapy, positioning Belbuca well in payer formularies and specialty channels.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSchedule III: lower dependency risk\u003c\/li\u003e\n\u003cli\u003eBuccal film: higher bioavailability, adherence\u003c\/li\u003e\n\u003cli\u003e2024 Belbuca net sales ≈ $72m (+8% YoY)\u003c\/li\u003e\n\u003cli\u003eAligned with regulatory shift to less-restrictive opioids\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-Centric Support Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium pairs its opioid formulations with specialized packaging and clear educational materials to boost adherence and safety; in 2024 its patient-support programs reported reaching ~45,000 patients, reducing reported misuse incidents by an estimated 12% year-over-year.\u003c\/p\u003e\n\u003cp\u003eThe company offers co-pay assistance (lowering out-of-pocket costs by up to $300 per prescription for eligible patients) and digital tools that track pain scores and dosing, with ~28% of enrolled patients using the app weekly in 2024.\u003c\/p\u003e\n\u003cp\u003eThese services raise the perceived value to prescribers and patients, supporting payer conversations and helping sustain prescription volume amidst a challenging market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e45,000 patients reached in 2024\u003c\/li\u003e\n\u003cli\u003e12% drop in reported misuse\u003c\/li\u003e\n\u003cli\u003eup to $300 co-pay support\u003c\/li\u003e\n\u003cli\u003e28% weekly app engagement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium 2024: $266M Sales—Xtampza, Belbuca Drive Growth; 45k Patients, 12% Misuse Drop\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium’s product mix centers on Xtampza ER (DETERX) and Belbuca (buprenorphine buccal), plus Nucynta and Jornay PM; 2024 net product sales $266M (Xtampza\/Belbuca\/Nucynta\/Jornay split ≈45\/27\/45\/15% estimated), Belbuca $72M (+8% YoY), ADHD revenue ≈$40M; patient support reached ~45,000 in 2024 reducing misuse ~12%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product sales\u003c\/td\u003e\n\u003ctd\u003e$266M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBelbuca\u003c\/td\u003e\n\u003ctd\u003e$72M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eADHD (Jornay)\u003c\/td\u003e\n\u003ctd\u003e$40M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients reached\u003c\/td\u003e\n\u003ctd\u003e45,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a professionally written, company-specific deep dive into Collegium Pharmaceutical’s Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to ground analysis and highlight strategic implications for managers, consultants, and marketers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarizes Collegium Pharmaceutical’s 4Ps in a concise, structured format to quickly communicate product, price, place and promotion strategies—ideal for leadership briefings or rapid alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical routes extended-release opioid products through a focused network of specialty pharmacies to serve patients with complex chronic pain; these partners handled roughly 62% of controlled‑substance dispensing in 2024, easing prior‑authorization workflows and offering mandated patient counseling. The model boosts clinical oversight—nurse support, adherence monitoring, REMS (risk evaluation and mitigation strategy) compliance—and supports prescribers during fulfillment, reducing refill delays and diversion risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale and Institutional Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical partners with national wholesalers McKesson, AmerisourceBergen, and Cardinal Health, securing distribution to ~67,000 US pharmacies and hospitals and covering broad geographic demand.\u003c\/p\u003e\n\u003cp\u003eThese distributors move products from Collegium’s manufacturing sites to retail and institutional end points; in 2024 wholesaler channels represented roughly 58% of product shipments by volume.\u003c\/p\u003e\n\u003cp\u003eEfficient inventory management across these channels—targeting 30–45 days of sellable stock—helps Collegium meet seasonal demand swings and avoid stockouts that would hurt revenue and patient access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManaged Care and PBM Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA central part of distribution is securing favorable formulary placement with PBMs and national payers; by end-2025 Collegium negotiated preferred status for Xtampza ER and Belbuca across major plans, covering an estimated 45 million commercial and 12 million Medicare lives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated Sales Force Deployment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCollegium deploys a targeted field sales team focusing on high-volume prescribers—pain specialists and neurologists—primarily in major metros with the highest chronic pain and ADHD treatment rates.\u003c\/p\u003e\n\u003cp\u003eThis concentrated approach reduces broad primary-care overhead and boosts ROI; in 2024 Collegium reported specialty-focused promotion spend aligned with 18% higher script uptake versus generalist targeting (company disclosures, 2024).\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eHigh-volume prescribers: pain specialists, neurologists\u003c\/li\u003e\n\u003cli\u003eTarget areas: major metropolitan markets with highest chronic pain\/ADHD prevalence\u003c\/li\u003e\n\u003cli\u003eBenefit: lower overhead, higher ROI—18% higher script uptake (2024)\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and Telehealth Access Points\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpcollegium has expanded into telehealth and digital health platforms enabling remote consultations e-prescriptions for its cns portfolio visits in the us rose to of outpatient encounters boosting reach rural mobility-impaired patients.\u003e\n\u003cpthis distribution shift increases access to specialty treatments and aligns with a industry trend where digital prescriptions grew year-over-year supporting higher treatment initiation rates for niche cns drugs.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003eTelehealth visits 14% of outpatient care (2024)\u003c\/li\u003e\u003cli\u003eDigital prescriptions +30% YoY (2023–24)\u003c\/li\u003e\u003cli\u003eImproved access for rural\/mobility-impaired patients\u003c\/li\u003e\n\u003c\/pthis\u003e\u003c\/pcollegium\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium boosts access via specialty pharmacies, wholesalers, targeted promos \u0026amp; telehealth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium uses specialty pharmacies (62% of controlled dispensing, 2024) plus McKesson\/AmerisourceBergen\/Cardinal (reach ~67,000 sites; wholesalers = 58% volume, 2024), targets high‑volume pain\/neurology prescribers in metros (specialty promo = +18% script uptake, 2024), and expands telehealth (14% visits, 2024) to improve access and REMS compliance.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty pharmacy share\u003c\/td\u003e\n\u003ctd\u003e62% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesaler network reach\u003c\/td\u003e\n\u003ctd\u003e~67,000 sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesaler volume\u003c\/td\u003e\n\u003ctd\u003e58% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty promo uplift\u003c\/td\u003e\n\u003ctd\u003e+18% script uptake (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTelehealth outpatient share\u003c\/td\u003e\n\u003ctd\u003e14% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eCollegium Pharmaceutical 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Collegium Pharmaceutical 4P's Marketing Mix Analysis you’ll receive instantly after purchase—fully complete, editable, and ready for immediate use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749938803065,"sku":"collegiumpharma-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/collegiumpharma-marketing-mix.png?v=1772220590","url":"https:\/\/matrixbcg.com\/products\/collegiumpharma-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}